1. Home/
  2. Compounds/
  3. tanespimycin:bortezomib (250:1 mol/mol)

tanespimycin:bortezomib (250:1 mol/mol)


SourcesNames Used
CTRPv2tanespimycin:bortezomib (250:1 mol/mol)
PharmacoGx tanespimycin:bortezomib (250:1 mol/mol)

Cell lines tested with tanespimycin:bortezomib (250:1 mol/mol)

797 cell lines have been tested with this compound, using data from 1 dataset(s).
CAL-29 urinary tract CTRPv21
CAL-120 breast CTRPv21
BFTC-909 urinary tract CTRPv21
253J-BV urinary tract CTRPv21
MKN1 stomach CTRPv21
KPL-1 breast CTRPv21
CAS-1 central nervous system CTRPv21
Download CSV

Tissues tested with tanespimycin:bortezomib (250:1 mol/mol)

25 tissues have been tested with this compound, using data from 1 dataset(s).
haematopoietic and lymphoid tissueCTRPv2135
central nervous systemCTRPv245
large intestineCTRPv239
Download CSV
Download Data as CSV

Top molecular features associated with response to tanespimycin:bortezomib (250:1 mol/mol)

Feature TypeStandardized
Nominal ANOVA
mRNA A1BG CTRPv2 AAC -0.041 0.3
mRNA A1CF CTRPv2 AAC 0.079 0.04
mRNA A2M CTRPv2 AAC 0.002 1
mRNA A2ML1 CTRPv2 AAC 0.044 0.3
mRNA A3GALT2 CTRPv2 AAC 0.034 0.4
mRNA A4GALT CTRPv2 AAC -0.13 0.0005
mRNA A4GNT CTRPv2 AAC 0.046 0.2
mRNA AAAS CTRPv2 AAC -0.047 0.2
mRNA AACS CTRPv2 AAC -0.02 0.6
mRNA AADAC CTRPv2 AAC 0.033 0.4
Download CSV